Clinical trial
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
NCT00384176 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00384176 |
|---|---|
| Title | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX |
| Official title | A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic… |
| Acronym | HORIZON III |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX), Leucovorin (in FOLFOX), Oxaliplatin (in FOLFOX) |
| Enrollment | 1,814 |
| Start date | Aug 30, 2006 |
| Primary completion | Nov 15, 2009 |
| Completion | Aug 19, 2015 |
| First posted | Oct 5, 2006 |
| Last update posted | Apr 14, 2017 |
| Countries | Australia, Austria, Belgium, Canada, Czechia, Egypt, Finland, France, Germany, Hungary, India, Israel and 16 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: